ticagrelor
Brilinta (ticagrelor) is a P2Y12 platelet inhibitor from AstraZeneca that prevents platelets from clumping into clots. It reduces heart attack and stroke risk in high-risk coronary artery disease and after acute coronary syndromes or myocardial infarction, and lowers stroke risk after minor ischemic stroke or high-risk TIA.
This page is based on FDA prescribing information and the EMA medicine record for ticagrelor, cross-checked with MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Platelets are the body's first responders, rushing to plug any leak by clumping together. After a stent or a heart attack, that clumping instinct can seal an artery instead of a wound. Ticagrelor turns down the rallying signal, the P2Y12 receptor, so platelets stay dispersed and blood keeps flowing, while still leaving enough clotting power for real injuries.
In simple terms
Ticagrelor belongs to the antiplatelet class. It blocks the P2Y12 receptor on platelets, a key signal that makes platelets collect and stick together. With the receptor blocked, platelets are less able to form the clots that can block arteries and cause a heart attack or stroke. It is taken by mouth, usually with aspirin, for people at high cardiovascular risk, including after acute coronary syndromes.
In depth
Ticagrelor is an orally active P2Y12 platelet inhibitor that reversibly binds the P2Y12 adenosine diphosphate receptor on platelets, inhibiting ADP-mediated platelet activation and aggregation. By preventing platelet collection and clot formation it reduces atherothrombotic events, including myocardial infarction and stroke. In the United States it is indicated to reduce the risk of a first MI or stroke in high-risk coronary artery disease and to reduce stroke risk after acute ischemic stroke or high-risk transient ischemic attack; in the European Union it is co-administered with acetylsalicylic acid for prevention of atherothrombotic events in acute coronary syndromes and in patients with a prior myocardial infarction.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How ticagrelor reversibly blocks the P2Y12 receptor on platelets
- Ticagrelor turns down the rallying signal, the P2Y12 receptor, so platelets stay dispersed and blood keeps flowing, while still leaving enough clotting power for real injuries.
- Ticagrelor is an orally active P2Y12 platelet inhibitor that reversibly binds the P2Y12 adenosine diphosphate receptor on platelets, inhibiting ADP-mediated platelet activation and aggregation.
- By preventing platelet collection and clot formation it reduces atherothrombotic events, including myocardial infarction and stroke.
- It is taken by mouth, usually with aspirin, for people at high cardiovascular risk, including after acute coronary syndromes.
Target: P2Y12 receptor on platelets
A platelet surface receptor that amplifies platelet activation and clumping; blocking it keeps platelets from collecting into the clots that cause heart attacks and strokes.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- To reduce the risk of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events
- To reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score of 5 or less) or high-risk transient ischemic attack
Approved uses in European Union
EMA- Co-administered with acetylsalicylic acid (ASA), for the prevention of atherothrombotic events in adult patients with acute coronary syndromes
- Co-administered with ASA, for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction that occurred at least one year ago and a high risk of developing an atherothrombotic event
Official sources
The statements on this page trace back to these records.
- Brilique (ticagrelor) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: ticagrelor prescribing information
U.S. Food and Drug Administration
- MedlinePlus: ticagrelor
MedlinePlus, U.S. National Library of Medicine
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.